Trial Profile
Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma; Cough
- Focus Proof of concept; Therapeutic Use
- Acronyms MUCOSA
- 13 Mar 2023 Planned End Date changed from 1 Dec 2022 to 30 Apr 2024.
- 13 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 31 Dec 2023.
- 16 Dec 2021 Status changed from not yet recruiting to recruiting.